Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion across the UK and Western Europe Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs. This investment will allow Panthera to further grow its network of dedicated …
Panthera have formed a partnership with Preston North End Football Club Community Trust. The team at Panthera attended the PNE vs Birmingham City game on the 15th of January promoting clinical trials. Fans who visited the Panthera van on game day also learnt more about additional clinical trials, such as those aimed at combating Osteoarthritis and Cardiovascular …
Valneva have released results from their phase 3 vaccine study (VLA2001). Stating that the trial has successfully met both co-primary end points. This trial compared the efficacy and effectiveness of the Valneva Covid-19 vaccine against the AstraZeneca vaccine. A total of 4012 people, aged 18 years and above were recruited to this clinical trial, across …
This month we have been busy vaccinating volunteers in North Manchester, Preston and North London for a new COVID prevention study. It has been an exciting time as we were the world’s first clinical trial site to administer the vaccine to volunteers in this study. The first participant to be vaccinated at our Rochdale clinic …
Independent clinical trial site management organisation (SMO), Panthera Biopartners, has appointed M&A and fundraisings adviser Chris Steed as a non-executive director. Chris has over 25 years’ experience as a corporate financier, working at Arthur Andersen, Deloitte and for the past 17 years as Founder and Managing Partner of Argyll Partners. Chris has acted as lead advisor …
As we all continue to adapt to the COVID-19 pandemic, we at Panthera are closely monitoring this rapidly evolving situation as well as remaining vigilant to support our patients and the NHS in any way we can. Panthera sites will remain open for business with significant additional precautions to prevent transmission of the COVID-19 virus. …
